Early noninvasive reliable biomarkers are among the major unmet needs in Parkinson’s disease (PD) to monitor therapy response and disease progression. Objective measures of motor performances could allow phenotyping of subtle, undetectable, early stage motor impairments of PD patients. This work aims at identifying prognostic biomarkers in newly diagnosed PD patients and quantifying therapy-response. Forty de novo PD patients underwent clinical and technology-based kinematic assessments performing motor tasks (MDS-UPDRS part III) to assess tremor, bradykinesia, gait, and postural stability (T0). A visit after 6 months (T1) and a clinical and kinematic assessment after 12 months (T2) where scheduled. A clinical follow-up was provided between 30 and 36 months after the diagnosis (T3). We performed an ANOVA for repeated measures to compare patients’ kinematic features at baseline and at T2 to assess therapy response. Pearson correlation test was run between baseline kinematic features and UPDRS III score variation between T0 and T3, to select candidate kinematic prognostic biomarkers. A multiple linear regression model was created to predict the long-term motor outcome using T0 kinematic measures. All motor tasks significantly improved after the dopamine replacement therapy. A significant correlation was found between UPDRS scores variation and some baseline bradykinesia (toe tapping amplitude decrement, p = 0.009) and gait features (velocity of arms and legs, sit-to-stand time, p = 0.007; p = 0.009; p = 0.01, respectively). A linear regression model including four baseline kinematic features could significantly predict the motor outcome (p = 0.000214). Technology-based objective measures represent possible early and reproducible therapy-response and prognostic biomarkers.

早期的无创可靠生物标志物是帕金森病 (PD) 监测治疗反应和疾病进展的主要未满足需求之一。运动表现的客观测量可以允许对 PD 患者的细微、无法检测的早期运动障碍进行表型分析。这项工作旨在确定新诊断的 PD 患者的预后生物标志物并量化治疗反应。40 名新发 PD 患者接受了基于临床和技术的运动学评估，执行运动任务（MDS-UPDRS 第三部分）以评估震颤、运动迟缓、步态和姿势稳定性 (T0)。6 个月后的访问 (T1) 和 12 个月后 (T2) 的临床和运动学评估（按计划进行）。在诊断后 30 至 36 个月（T3）提供临床随访。我们对重复测量进行了方差分析，以比较基线和 T2 时患者的运动学特征，以评估治疗反应。在基线运动学特征和 T0 和 T3 之间的 UPDRS III 评分变化之间运行 Pearson 相关性检验，以选择候选运动学预后生物标志物。创建多元线性回归模型以使用 T0 运动学测量预测长期运动结果。多巴胺替代疗法后，所有运动任务均显着改善。在 UPDRS 评分变化和一些基线运动迟缓（脚趾敲击幅度减少，选择候选的运动学预后生物标志物。创建多元线性回归模型以使用 T0 运动学测量预测长期运动结果。多巴胺替代疗法后，所有运动任务均显着改善。在 UPDRS 评分变化和一些基线运动迟缓（脚趾敲击幅度减少，选择候选的运动学预后生物标志物。创建多元线性回归模型以使用 T0 运动学测量预测长期运动结果。多巴胺替代疗法后，所有运动任务均显着改善。在 UPDRS 评分变化和一些基线运动迟缓（脚趾敲击幅度减少，p  = 0.009）和步态特征（手臂和腿的速度，从坐到站的时间，分别为p  = 0.007；p  = 0.009；p  = 0.01）。包括四个基线运动学特征的线性回归模型可以显着预测运动结果 ( p  = 0.000214)。基于技术的客观测量代表可能的早期和可重复的治疗反应和预后生物标志物。